P-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 243-250

  Sayed, Douaa ^a   Badrawy, Hosny ^a   Gaber, Noha ^a   Khalaf, Muhammed R ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

Bcr abl; Chronic myeloid leukemia; Imatinib; Stat3

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE; PYRIMIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ADULT; ARTICLE; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE REPRESSION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THERAPY RESISTANCE; CASE CONTROL STUDY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION;

ADULT; ANTINEOPLASTIC AGENTS; BENZAMIDES; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASES; PYRIMIDINES; STAT3 TRANSCRIPTION FACTOR;

EID: 84892527855     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.11.012     Document Type: Article

References (21)

1. Deininger M., O'Brien S.G., Guilhot F., et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 2009, 114:1126.
2. Misaghian N., Ligresti G., Steelman L.S., et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009, 23:25-42.
3. Jamieson C.H. Chronic myeloid leukemia stem cells. Hematol Am Soc Hematol Educ Program 2008, 2008:436-442.
4. Preudhomme C., Guilhot J., Nicolini F.E., et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010, 363:2511-2521.
5. Naka K., Hoshii T., Hirao A. Novel therapeutic approach to eradicatetyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010, 101:1577-1581.
6. Chen Y., Li D., Li S. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Cell Cycle 2009, 8:3488-3492.
7. Redell M.S., Ruiz M.J., Alonzo T.A., Gerbing R.B., Tweardy D.J. Stat3 signaling in acute myeloid leukemia: ligand-dependent and independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 2011, 117:5701-5709.
8. Wegrzyn J., Potla R., Chwae Y.J., et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
9. Hoelbl A., Schuster C., Kovacic B., Zhu B., Wickre M., Hoelzl M.A., et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2010, 2:98-110.
10. Nair R.R., Tolentino J.H., Hazlehurst L.A. Role of STAT3 in transformation and drug resistance in CML. Front Oncol J 2012, 2:30.
11. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon. 4th ed.
12. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management Recommendations of the European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
13. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
14. Gaiger A., Henn T., Horth E., Geissler K., Mitterbauer G., Maier-Dobersberger T., et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995, 86:2371-2378.
15. Holyoake D.T. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 2001, 113:11-23.
16. Hevehan D.L., Miller W.M., Papoutsakis E.T. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood 2002, 99:1627-1637.
17. Redell Michele S., Tsimelzon A., Hilsenbeck S.G., Tweardy D.J. Conditional overexpression of Stat3 in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern. J Leukoc Biol 2007, 82:975-985.
18. Bewry N.N., Nair R.R., Emmons M.F., Boulware D., Pinilla-Ibarz J., Hazlehurst L.A. Stat3 contributes to resistance toward bcr-abl inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008, 7(10):3169-3175.
19. Nair R.R., Tolentino J.H., Argilagos R.F., Zhang L., Pinilla-Ibarz J., Hazlehurst L.A. Potentiation of Nilotinib mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res 2012, 36(6):756-763.
20. Sims J.T., Ganguly S.S., Bennett H., Woodrow Friend J., Tepe J., Plattner R. Imatinib Reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS ONE 2013, 8(1):e55509.
21. Coppo P., Flamant S., De Mas V., Jarrier P., Guillier M., Bonnet M.L., et al. bcr-abl activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006, 134:171-179.